The metabotropic glutamate receptors (mGluR) consist of a family of eight G-protein-coupled receptors that differ in their function, distribution and physiological roles within the central nervous system. In recent years substantial efforts have been made towards developing selective agonists and antagonists which have proven useful for elucidating their potential as novel targets for the treatment of psychiatric and neurological diseases. In the present review we will provide an update of the recent developments of functional allosteric modulators of the mGluR family and explore their therapeutic potential for anxiety/depression, schizophrenia, epilepsy/stroke, pain and Alzheimer's, Parkinson's and Huntington's diseases. © Basic & Clinical Pharmacology & Toxicology 2005.
CITATION STYLE
Ritzén, A., Mathiesen, J. M., & Thomsen, C. (2005, October). Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic and Clinical Pharmacology and Toxicology. https://doi.org/10.1111/j.1742-7843.2005.pto_156.x
Mendeley helps you to discover research relevant for your work.